Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology. Its phase II drug candidate, Foxy-5, focuses on colon cancer and intends to decrease tumors and reduce cancer spread. Our fair value range suggests a significant upside potential in the share, and we argue that upcoming interim data and a potential licensing deal are two major catalysts in the short term.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/